On Oct 24, major Wall Street analysts update their ratings for $Quest Diagnostics (DGX.US)$, with price targets ranging from $165 to $185.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $165 to $185.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $154 to $168.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and maintains the target price at $165.
Baird analyst Eric Coldwell upgrades to a buy rating, and adjusts the target price from $157 to $182.
Truist Financial analyst David S Macdonald maintains with a hold rating, and adjusts the target price from $165 to $172.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The revised guidance for Quest Diagnostics is primarily attributed to the integration of LifeLabs, accompanied by sustained high utilization trends. The defensive characteristics of Quest, especially around an election cycle, and the more secure estimates for future years are viewed positively.
Quest Diagnostics delivered a strong third-quarter performance, characterized by exceeding expectations and maintaining earnings guidance even amid hurricane challenges. Additionally, the company provided an encouraging preliminary outlook for fiscal year 2025.
The elevated estimates for Quest Diagnostics come on the heels of robust third-quarter performances and a strong preliminary outlook for 2025. The company's prospects for earnings remain promising, bolstered by consistent healthcare utilization trends, market share expansions, and a favorable mix.
The lab sector is viewed positively for its prospects in 2025, with the belief that there shouldn't be hesitation in favoring one company on the basis of cost alone. Quest Diagnostics is recognized for having several catalysts that may contribute to hastened growth in 2025, bolstered by a series of eight acquisitions expected to complete in 2024, which should sustain the company's momentum into the following year.
Here are the latest investment ratings and price targets for $Quest Diagnostics (DGX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月24日，多家华尔街大行更新了$奎斯特诊疗 (DGX.US)$的评级，目标价介于165美元至185美元。
花旗分析师Patrick B Donnelly维持买入评级，并将目标价从165美元上调至185美元。
巴克莱银行分析师Stephanie Davis维持持有评级，并将目标价从154美元上调至168美元。
Evercore分析师Elizabeth Anderson CFA维持持有评级，维持目标价165美元。
贝雅分析师Eric Coldwell上调至买入评级，并将目标价从157美元上调至182美元。
储亿银行分析师David S Macdonald维持持有评级，并将目标价从165美元上调至172美元。
此外，综合报道，$奎斯特诊疗 (DGX.US)$近期主要分析师观点如下：
奎斯特诊疗的修订指导主要归因于与LifeLabs的整合，以及持续稳定的高利用率趋势。奎斯特的防御特性，特别是在选举周期周围，以及对未来几年更为安全的预估被视为积极。
奎斯特诊疗在第三季度表现强劲，超出预期并在飓风挑战中维持盈利指引。此外，该公司为2025财年提供了令人鼓舞的初步展望。
奎斯特诊疗的预估提升得益于强劲的第三季度业绩以及2025年强劲的初步展望。公司的盈利前景仍然有希望，得益于持续稳定的医疗利用趋势，市场份额扩张和有利的组合。
实验室板块在2025年的前景被看好，人们认为不应仅基于成本而犹豫支持某一公司。奎斯特诊疗因拥有多个可能有助于2025年增速的催化剂而受到认可，这些催化剂得到有望在2024年完成的八项收购的支持，这将使公司的势头延续到接下来的一年。
以下为今日5位分析师对$奎斯特诊疗 (DGX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
